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Abstract 
The completion of the human genome project in 2003 represented a major scientific 
landmark, ushering in a new era with hopes and expectations of fresh insights into disease 
mechanisms and treatments. In IBD, many important discoveries soon followed, notably the 
identification of more than 200 genetic susceptibility loci and characterisation of the gut 
microbiome (1). As ‘big data’, driven by advances in technology, becomes increasingly 
available and affordable, individuals with IBD and clinicians alike yearn for tangible 
outcomes from the promise of ‘precision medicine’ – precise diagnosis, monitoring and 
treatment. Here we provide a commentary on the prospects and challenges of precision 
medicine and biomarkers in IBD. We focus on the three key areas where precision IBD will 
have the most impact: (1) disease susceptibility, activity and behaviour; (2) prediction of drug 
response and adverse effects; (3) identification of subphenotypic mechanisms to facilitate 
drug discovery and selection of new treatments in IBD. 
 
Precision medicine in IBD  
Precision medicine is a major priority in health care, now recognised by all major 
stakeholders including governments, the pharmaceutical industry, clinicians and patients. In 
January 2015, United States President Barack Obama announced the Precision Medicine 
Initiative® (PMI): a concerted effort by multiple government agencies and backed by $215 
million in federal funds to help facilitate a greater understanding of individual disease 
variability and its clinical translation (2). A major component is the PMI Cohort Program, an 
ambitious plan to build a national research cohort of more than one million participants in a 
participant-centred, data-driven framework with integrated multi-omic profiling. The PMI 
working group’s report (3) identified key scientific opportunities including a number relating to 
the importance of biomarkers (Box 1). Similarly, the Chinese government has plans to invest 
20 billion yuan (around US $3 billion) to support precision medicine research by 2030. Here 
in the United Kingdom (UK), the 100,000 genomes project was launched in 2012 with the 
goal of large-scale integration of genetic information and health records from the National 
Health Service (http://www.genomicsengland.co.uk). In the same year, the National 
Phenome Centre was launched in the UK, offering broad access to exploratory and targeted 
high-throughput metabolic phenotyping and computational biology facilities. These massive 
undertakings are game changers in the field of biomarker discovery and validation.  
In IBD, successful international partnerships in genetics and microbiome research already 
provide grounds for realistic optimism. A major concern remains the wide-ranging nature of 
the stochastic elements of IBD, which represent formidable hurdles with respect to study 
design and measurable outcomes. A recent study published in Cell (4) provides a concrete 
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conceptual framework on how unbiased, data-driven development of personalized medicine 
approaches may be applicable to IBD. In this proof-of-concept study, post-prandial glucose 
responses to 46,898 meals were measured in 800 patients using continuous blood glucose 
monitoring. Combining patient-entered data with clinical and microbiota profiles, a 
computational algorithm was developed that accurately predicted personalized glycaemic 
response in a separate cohort. Notably, this algorithm was used in a follow-up dietary 
intervention study which yielded significantly lower post-prandial glucose levels (4). In our 
field, current creative research approaches (discussed in detail later) are now beginning to 
integrate across molecular datasets (e.g. genetic + microbiome), override traditional 
boundaries of disease classifications (UC vs. CD), target previously underexplored biological 
systems (e.g. virome and endogenous DAMPs) and most notably, increasingly rely on 
patient input using new technological applications to characterise the ‘exposome’ in IBD 
(5)(6)(7). Hence, a new theme of recombinant innovation is emerging with synergy arising 
from novel ideas within established and fresh datasets. 
 
IBD biomarkers in clinical practice - the story so far 
Numerous potential genetic, blood-based, faecal, microbial and immunological biomarkers 
have been proposed in IBD (8) (Table 1). This has recently been extensively reviewed 
(9)(10)(11)(12). However, apart from a few notable exceptions, biomarkers have not yet 
found widespread clinical application in IBD practice for a variety reasons (Box 2). We 
highlight three examples of ‘biomarkers’ that have roles in clinical practice, namely faecal 
calprotectin (FC), anti-TNF antibodies and thiopurine methyltransferase (TPMT) activity 
measurements. FC is a screening tool for gut inflammation (13) and to measure disease 
activity in IBD (14). More recently, the potential to use FC in innovative ways has been 
explored including as a predictive tool (e.g. to identify disease recurrence in post-operative 
CD (15)) and as a secondary end-point in IBD clinical trials. Detection of anti-TNF antibodies 
allows for expedient switching to an alternative drug (16) and avoids conventional dose 
escalation which is often futile, expensive and potentially hazardous (17). A recent 
randomized controlled trial in the setting of secondary loss of response to infliximab 
compared conventional dose intensification with an algorithm based approach based on 
serum infliximab levels and antibodies (18). Here, management dictated by drug levels and 
antibodies was found to be cost effective with no reduction in clinical efficacy. TPMT 
measurement can screen for those who are likely to experience life threatening leukopenia 
from thiopurines (19) and those who would benefit from a reduced initial dose. Although of 
some clinical benefit, these currently available examples provide some perspective to the 
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enthusiasm towards Precision Medicine, highlighting the wide gulf between what clinicians 
currently have at their disposal and the ambitious aspirations for the near future.  
 
IBD big data: Sink or swim?  
The critical question is: are we on the cusp of a therapeutic revolution underpinned by the 
inexorable wave of big data, or will we end up drowning in a sea of potential biomarkers that 
we cannot translate into clinical practice?  A number of critical enablers allow for optimism 
(Figure 1). First, government and industry interest and investment will continue to improve 
the development of large-scale prospective cohorts. Ambitious biobank projects such as the 
recently launched UK-wide IBD BioResource (www.ibdbioresource.nihr.ac.uk) and the 
aforementioned PMI Cohort Program will help overcome this first obstacle for novel IBD 
biomarker discovery and validation. Second, we expect advances in high throughput 
technology to allow for quicker, cheaper and more efficient testing of large biobanks. Costs 
for DNA sequencing have shrunk by more than 10 million fold since 1998 – something 
almost inconceivable at the time. It is similarly difficult to comprehend what might be possible 
in the future. In concert, advances in computational power will continue to facilitate 
production and analysis of massive amounts of accrued IBD –omics data. Third, we foresee 
the influence of the exposome being clarified from an increasing emphasis on patient 
inputted data. Technological advances such as personal mobile devices for real-time 
monitoring and electronic health record integration will provide a platform for prospective and 
progressive data collection. In IBD, there is increasing use of real-time feedback of clinical 
information, environmental factors and disease activity (e.g. home FC kits) back to clinicians 
and researchers (20).  
These advancements require even closer levels of cooperation and collaboration between 
researchers. Furthermore, there is a greater need for more creative analytical approaches 
that will involve a model of continuous learning and analysis. Centres of excellence 
dedicated to Precision Medicine and Big Data analyses are now currently being set up 
globally.  Some health systems may be better equipped to provide the long term biological 
data and clinical follow-up that captures the disease population in its widest sense (e.g. 
arguably, the UK National Health System).  
Notwithstanding all these major interventions, there is a need for a dose of realism. In cancer 
research, where investment has been far greater, there has been a decrease in the number 
of FDA approved protein biomarkers over the last decade (21). In IBD, it is notable that 
biomarkers in existing use such as faecal calprotectin were found through hypothesis based 
investigation (22) rather than high throughput methods or in silico database analysis. 
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Presently, discovery-based approaches are burdened by a number of significant challenges 
(summarized in Box 3). In particular, selection bias from convenience sampling and data 
overfitting can result in over-interpretation of ‘significant’ p-values, potentially wasting 
valuable resources on random noise. For example, a host of studies have identified genetic 
polymorphisms as predictors of therapeutic response in IBD (9) but these have not been 
consistently replicated. There remains room for advancements based on discoveries in 
related inflammatory conditions, serendipity and organic scientific thinking, although big data 
now forms the ground for the generation of new hypotheses. 
 
Precision Medicine in IBD: Recent progress 
Multiple lines of evidence show progress towards Precision Medicine and we provide a brief 
overview of several promising studies in three key areas in IBD (disease susceptibility, 
activity and behaviour; prediction of drug response and adverse effects; and identification of 
subphenotypic mechanisms for drug selection and discovery).  Collectively, they highlight a 
few recurrent themes. First, the enormous potential of how big data can be even more 
powerful when different data platforms are integrated. Second, the process involved in 
validating these increasingly complex findings remains difficult, as does the path for 
biomarkers to reach clinical application. In this context, it seems likely that the future maybe 
based on computational predictive modelling, incorporating many biomarkers (as shown by 
Zeevi et al), and evident in artificial intelligence systems that permeate current daily living 
(e.g. weather forecasting and voice recognition search systems). This challenges the 
traditional criteria for a good biomarker being simple, accurate, easy to perform, minimally 
invasive, cheap, rapid and reproducible. Hence, some re-orientation of IBD patients’ and 
clinicians’ perspectives may be needed. 
Disease susceptibility, activity and behaviour  
Here genetic studies lead the way with the latest meta-analysis now involving 50 000 IBD 
individuals implicating more than 200 susceptibility loci (23)(24). This information provided 
hitherto unknown insights into disease mechanisms and biological pathways such as 
autophagy and IL23/Th17. The role for genetic data in predicting susceptibility, activity and 
disease behaviour is however less strong. For example, the strongest genetic signal, NOD2 
status has been associated with ileal and fibrostenosing disease but carriage of the NOD2 
mutant allele is uncommon. Genetic information allied with other biological data (e.g. pheno-
genomic status), maybe more informative. A combination of clinical, serological and 
genotypic data has been used to help predict the risks of surgery in CD (25). Recently, a 
study of 29,838 IBD patients which tested for genetic-phenotype associations found that 
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predictive models based on generated genetic risk scores strongly distinguished colonic 
from ileal CD (26).  
Beyond genetics, epigenetics is emerging as a further tier of information that could 
complement genome wide association studies (GWAS) (27). Several epigenome wide 
studies have been published in IBD and other diseases (28–32). These studies identify 
epigenetic mechanisms as a potential interface between genetics and disease. Highly 
significant enrichment of methylation changes have been shown to occur around GWAS 
single nucleotide polymorphisms, in particular the HLA region and MIR21 (28). The 
Roadmap Epigenomics Project recently published the most comprehensive epigenomic 
reference providing information on 111 new reference epigenomes and how these control 
gene expression in humans (33). Equally, other epigenetic mechanisms such as miRNAs 
are being explored for their roles in IBD pathogenesis (34). These short strands of non-
coding RNA (~22nt long) have been shown to regulate key GWAS pathways in IBD including 
autophagy and epithelial barrier integrity (34).  
The microbiome or ‘other genome’ – the collective genome of the gut microbiota –  
represents a further giant dimension in big data in IBD and other complex multifactorial 
conditions such as diabetes and obesity (4,35–37). The NIH-funded Human Microbiome 
Project Consortium has generated in-depth data on the genomic information and microbial 
community structure and function in humans. Some early studies show potential for clinical 
translation towards Precision Medicine. In the largest study of treatment naïve CD patients to 
date, Gevers and colleagues found ileal microbiome signatures were predictive of CD and 
observed this even in the absence of overt inflammation (38). In one recent prospective 
study of paediatric IBD receiving anti-TNF therapy, faecal microbial diversity resembled 
controls in patients who responded to anti-TNF therapy versus non-responders (39). This 
shift in microbial diversity in responders was also seen in a paediatric UC study of steroid 
response (40). Furthermore, microbial populations may help predict disease course as 
illustrated by a study of post-operative recurrence in CD, where a decreased population of 
Faecalibacterium prausnitzii in the resected ileum correlated with increased risk of 
recurrence (41). We anticipate rapid progress in this area with many opportunities for the 
public and patients to contribute their faecal samples for analysis (e.g. the American Gut 
Project). 
Away from predicting susceptibility and behaviour in IBD, there is an unmet need for 
sensitive biomarkers to measure gut mucosal inflammation to provide objective data on 
disease activity and guide response to treatment. Presently, C-reactive protein (CRP) and 
faecal calprotectin have better negative predictive values and are thus more useful in 
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excluding significant inflammatory signals. Some progress can be expected in modalities to 
image inflammation (e.g. MRI) with or without the use of specific in-vivo labelling of 
inflammatory cells or targets. A recent study used confocal laser endomicroscopy to detect 
fluorescent antibody labelled membrane-bound TNF (mTNF) in intestinal immune cells of 25 
CD patients (42). Patients with high numbers of mTNF+ cells were more likely to respond to 
adalimumab at week 12 than those with low amounts of mTNF+ cells (92% versus 15%). 
Furthermore, a re-thinking of ways to measure established biomarkers such as measuring 
serum (rather than faecal) calprotectin (43) may improve the performance and applicability of 
these tests. In search of better disease activity prediction, current approaches as exemplified 
by the EMBARK study, assess a panel of biomarkers by their correlation with endoscopy 
and radiological findings as the best reference measure (44). However, although such 
reference measures capture disease extent; location and burden well, they are not specific 
enough to evaluate disease behaviour, complications and progression (44,45). As will be 
discussed later, better biomarkers of activity may come from a refined approach measuring 
specific downstream effects of the biological pathway targeted (e.g. Th17-family of cytokines 
in IL23/IL17 inhibition). 
 
Prediction of drug response and adverse effects 
Exploiting the wealth of genetic data, the combination of phenotypic information with multiple 
susceptibility loci has been shown to be predictive of primary non-response in anti-TNF 
therapy in paediatric IBD (46). There have been some notable successes in transcriptomics 
(gene expression) in IBD. Lee et al showed that CD8+ T-cell immune signatures are better 
at predicting disease course than traditional clinical or serological markers (47). Hence, this 
approach is useful to select individuals that might benefit from more aggressive medical 
treatment. At the mucosal level, one study of infliximab in UC used gene signatures to 
separate responders from non-responders with 95% sensitivity and 85% specificity (48).  
In terms of predicting adverse effects, a recent study found that a nonsynonymous single-
nucleotide polymorphism in NUDT15 has a greater effect than TPMT variants in patients of 
Korean ancestry in predicting thiopurine induced leukopenia (49). GWAS of azathioprine 
induced pancreatitis found increased susceptibility for HLA-DQA1-HLA-DRB1 variants with a 
2.5 fold increased risk in heterozygotes and a 5 fold increased risk in homozygotes at 
rs2647087 (50). Although an important finding, this potential biomarker highlights some of 
the difficulties encountered in translation to the clinic. For example, the low pre-test 
probability of pancreatitis means that even in the highest risk homozygotes, there is an 83% 
chance of taking thiopurines without developing pancreatitis. Would this justify the exclusion 
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of thiopurines in these patients? Perhaps not, but in a future of greater therapeutic options, 
this may be more feasible and in the meantime, will improve risk counselling and awareness. 
In addition, the number needed to test in this study was 76, making it an expensive option for 
screening. However, cheaper point of care testing in the future, and the possible 
combination with other biomarkers could change the economics of such a test.  
 
Identification of subphenotypic mechanisms to facilitate drug discovery and selection 
of new treatments  
IBD clinicians will have increasing number of drugs available with over 20 currently in the 
developmental pipeline (51)(52). Rather than a sequential approach of trying one drug after 
another, one of the goals for Precision Medicine is to identify individuals or disease 
phenotypes that are better suited for a particular drug from the outset (e.g. anti-leukocyte 
migration versus anti-TNF). This direction is appealing and cogent where recent advances in 
oncology and virology have shown the way. In breast cancer, human epithelial growth factor 
(HER2) positivity provides prognostic information (more aggressive phenotype with higher 
recurrence rates) as well as therapeutic choice (response to monoclonal antibodies targeting 
HER2 such as trastuzumab) (53). In metastatic colorectal cancer, KRAS gene mutations 
predict response to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody 
therapy (54). Notably, the early studies were performed based on a hypothesis developed 
from an understanding of EGFR biology (55); subsequent retrospective subset analysis of 
randomized controlled trials provided strong evidence for clinical use. In non-small cell lung 
cancer, mutations in multiple oncogenes including ALK and EGFR can help direct tyrosine 
kinase therapy (56). In hepatitis C, prior to the direct acting antiviral revolution, IL28B 
genotype helped predict the likelihood of sustained viral response to interferon and ribavirin 
therapy.  
The current case of anti-TNF is instructive and highlights the difficulties ahead in developing 
a biomarker based decision-making model. Although therapeutic drug monitoring and 
antibody testing are important to inform dosing and the decision to switch biologic, there is 
currently no clinically useful predictor of anti-TNF response prior to initiation. Retrospective 
studies and post-hoc analysis of large clinical trials found a number of phenotypic, 
demographic and biochemical markers that help predict response but the effect size and 
evidence is not convincing enough to be clinically useful (57). At a molecular level, attempts 
were made to investigate anti-TNF response based on TNF-α gene polymorphisms, but 
these produced inconsistent results (58). Baseline TNF levels were found to be higher in 
those who did not respond to infliximab at 10 weeks (59), but a subsequent larger study did 
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not find any such relationship (60). Prediction of anti-TNF response has also been attempted 
with in vivo imaging (61) and mucosal gene expression signatures (62)(48). Furthermore, 
there are ongoing research efforts to elucidate the factors that determine response to anti-
TNF drugs, such as the multi-centre UK PANTS study in active luminal Crohn’s disease. A 
more incisive and economical investigative model might be to start from a fresh platform, by 
building the study of biomarkers into clinical trials in IBD. 
Incorporating biomarkers in clinical trials 
The unexpected failures of secukinumab (63) and tofacitinib (64) in CD, anrukinzumab in UC 
(65) and abatacept in CD and UC (66) have raised the question of whether molecular based 
stratification with biomarkers based on underlying disease mechanisms could reveal 
subgroups within the traditional CD and UC groups, who would selectively benefit from 
certain therapies (Figure 2). A number of large clinical trials are seeking to incorporate 
biomarkers into trial design (67), with the notion that biomarker development and clinical trial 
design should operate hand-in-hand. Multiplex IBD biomarker panels are created at 
diagnosis to obtain a snapshot of a patient’s molecular disease profile. These biomarker 
profiles can be used in post hoc analyses to investigate their relationship to drug response 
(Figure 2).  
Incorporating new biomarkers in clinical trials however, is challenging and expensive. The 
cost of drug development is inversely related to the size of the target population, which is 
necessarily smaller in personalized therapy. Furthermore, stratification using all possible 
biomarker combinations is impractical given resource and trial participant limitations. At 
some point, decisions need to be made regarding which biomarkers are incorporated into 
trials. Another challenge is the standardization of classification/stratification among studies. 
Although more information, including molecular profiling, is generally better than less 
information, distinct and stable classification also has its advantages including comparability 
between trials, and improved communication between clinicians and researchers. 
Increasingly targeted therapies will require more defined biomarkers to measure their effects 
on the respective biological pathways. This sets the scene for stratified clinical trials as seen 
in oncology for example. 
Conclusion: Meta-ideas in IBD 
Clinicians long for a future where a newly diagnosed IBD patient can have his/her genetic, 
microbiome and immune profile measured at the outset; then matched to the most 
appropriate biologic or immunosuppressive treatment based on likelihood of 
response/adverse effects. These IBD individuals will be informed of what ‘exposome’ to 
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modify and report on their disease activity using the set of optimal biomarkers. At all levels, 
one can expect a continuous feedback of new data from respective patients, which will 
further improve the dataset for biomarker discovery.  
For some time, the barrier for real progress has been affordable access to big data. This is 
now within reach. The digital age now involves patients as active contributors to research 
data and creates an expansive network of researchers spanning across the traditional 
disease, biological pathway and systems’ boundaries. The digitalisation of clinical data and 
penetration of artificial intelligence into science are entirely new dimensions in play. 
Notwithstanding all these factors, we believe that the force that will shape Precision 
Medicine in IBD will be the focus on meta-ideas - ideas that will further accelerate the 
production or transmission of new ideas. Established organisations such NASA increasingly 
rely on ‘open innovation’ or crowdsourcing to find new solutions to their most difficult and 
intractable problems. The availability of ‘big data’ is no longer the rate-limiting step to 
progress; instead, it is the clinician or researcher’s ingenuity in leveraging these assets into 
new knowledge.  
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FIG 1: CRITICAL ENABLERS IN THE FLOW OF PRECISION MEDICINE IN IBD 
 
FIG 2: INCORPORATING BIOMARKERS INTO THE DESIGN OF CLINICAL TRIALS IN IBD 
 
TABLE 1: Summary of potential and current applications of biomarkers relevant to the 3 key areas of Precision Medicine in IBD. 
Disease susceptibility, activity and behaviour Prediction of adverse effect and 
therapeutic response 
Identification of subphenotypic mechanism 
Susceptibility/behaviour 
Genetics and serological markers 
NOD2, ATG16L1, IL23R 
ASCA, ANCA 
 
Microbial  
Compositional microbiome shifts (Enterobacteriaceae, 
Enterococcaceae, Lachnospiraceae (Blautia, Dorea), Prevotella) 
Decreased Faecalibacterium prausnitzii 
Increased adherent invasive E. coli 
 
Activity 
CRP, ESR, serum albumin, stool calprotectin, lactoferrin, 
S100A12, Magnetic resonance imaging 
Composite stool calprotectin and blood MMP9 and IL-22 
 
Adverse effect 
TPMT  
NUDT15 
HLA-DQA1-HLA-DRB1  
 
Therapeutic response 
Antibodies towards TNF 
Anti-TNF and thiopurine metabolites 
mTNF+ in intestinal immune cells by 
confocal laser endomicroscopy 
 
 
Cytokines and transcriptomics 
IL-13, IL-23 
Th17 cytokines (IL-17A, IL-17F, IL-22) 
IL-6, IL-1, IL-8. IL-10, TNFα 
CD8-T cell signatures 
Soluble ST2 and IL-33 
Mucosal indoleamine 2,3 dioxygenase-1 
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BOX 1 
BIOMARKER FOCUSSED SCIENTIFIC OPPORTUNITIES IDENTIFIED BY THE PMI 
• Biomarker discovery for identification of individuals with a higher risk of developing 
disease to help more rational prevention efforts 
• Interrogation of the wide variation in therapeutic response and adverse reactions 
• Novel classification systems which transcend the existing grouping based on 
symptoms, signs and laboratory results by using molecular characterisation 
• Using biomarkers to assign patients into a variety of clinical trials targeting subsets 
based on these biomarkers to help with development of novel therapies 
• Translating pre-existing environmental and genetic risk factors into conclusions on 
disease causes and population impact with population based cohort studies as 
well as identifying new associations. 
 
 
BOX 2 
WHY HAVE MOST POTENTIAL IBD BIOMARKERS NOT FOUND THEMSELVES IN 
WIDESPREAD CLINICAL USE? 
• Failures on the classic qualities of an ideal biomarker (68) (simple, accurate, easy 
to perform, minimally invasive, cheap, rapid, reproducible) 
• Unclear or uncertain clinical utility: i.e. does not provide clinically useful information 
upon which to make decisions 
a. low sensitivity/specificity 
b. low prognostic/predictive values 
• Lack of validation in independent cohorts or have had inconsistent results when 
validation has been attempted.  
• Some areas (such as microbiome based biomarkers) are in their infancy 
 
 
BOX 3 
CHALLENGES WITH –OMICS RESEARCH 
• Large costs associated with biomarker validation for those biomarkers proposed by 
unbiased -omics testing 
• Potential confounders including interaction between the different ‘omes’ (e.g. 
microbiome studies with effect of host genome), disease activity, duration, location 
and effects of drug treatment, study design, heterogeneous cohorts 
• Selection bias using convenience sampling 
Page 12 of 23
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
American Journal of Gastroenterology
For Peer Review
• Increased flexibility and non-linearity in algorithms leading to overfitting 
• Lack of support from pharmaceutical companies not wanting to fragment markets 
• Reluctant adoption and acceptance by physicians and patients 
• So far, mainly cross-sectional studies i.e. one point in time rather than continuous 
prospective studies  
• Electronic medical record integration – difficulties in standardization, poor quality 
and granularity of inputted data. National approach easier in some countries (e.g. 
UK with NHS) than others e.g. USA 
• Privacy and data security 
• Standardization of all steps in the process of biomarker discovery is optimal but in 
practice, difficult to achieve.  
• Teamwork and collaboration across institutions (particularly critical in relatively low 
incidence diseases such as IBD) with use of standard protocols and large cohorts. 
 
POTENTIAL SOLUTIONS 
• Data-driven approaches such as network interference 
• Prospective studies with multipl  time points 
• Standardized method of sample acquisition 
• Use of homogenous patient subsets and studies of subjects with no prior medical 
therapy 
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CURRENT KNOWLEDGE AND WHAT IS NEW HERE 
• Despite recent progress in understanding IBD pathogenesis, there are only a few 
biomarkers (faecal calprotectin and C-reactive protein) that are widely used in 
clinical practice. 
• Successful biomarker discovery is hampered by many factors particularly, the 
wide-ranging nature of the stochastic elements of IBD, which represent formidable 
barriers to study design and measurable outcomes. 
• ‘Big data’ in IBD (encompassing including host multi-omic profile, microbiome and 
exposome) and increasingly powerful computational approaches are now within 
reach. 
• Precision Medicine (PM) Initiative is a major program focused towards achieving a 
greater understanding of individual disease variability and its clinical translation. 
Together with many international stakeholders involved in PM, this impetus 
represents a game-changer directly relevant to IBD. 
• We focus on the three key areas where precision IBD will have the most impact: 
(1) disease susceptibility, activity and behaviour; (2) prediction of drug response 
and adverse effects; (3) identification of subphenotypic mechanisms to facilitate 
drug discovery and selection of new treatments in IBD. 
• ‘Meta-ideas’, the pipeline to generate of new and innovative ideas to leverage ‘Big 
data’ into tangible clinical translation now represents the most exciting challenge in 
biomarker discovery in IBD. 
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